Flexible dose open trial of Vijayasar in cases of newly-diagnosed non-insulin-dependent diabetes mellitus. Indian Council of Medical Research (ICMR), Collaborating Centres, New Delhi

    Research output: Contribution to journalArticle

    35 Citations (Scopus)

    Abstract

    A flexible dose open trial was undertaken in four centres in India to evaluate the efficacy of an Ayurvedic drug Vijayasar (Pterocarpus marsupium) in the treatment of newly-diagnosed or untreated non-insulin dependent diabetes mellitus (NIDDM). By 12 wk, control of blood glucose (both fasting and postprandial levels) had been attained in 67 (69%) of 97 patients studied, and the dose on which control was attained was 2 g of the extract in about 73 per cent of the patients, 3 g in about 16 per cent and 4 g in 10 per cent of the patients. Four patients had to be withdrawn from treatment due to excessively high postprandial blood glucose levels. Among the 93 patients who completed 12 wk of treatment, both the fasting and postprandial blood glucose levels fell significantly (P <0.001), by 32 and 45 mg/dl at 12 wk from the initial means of 151 and 216 mg/dl respectively. Mean HbA1c decreased significantly (P <0.001) to 9.4 per cent at 12 wk from the initial mean of 9.8 per cent. No significant change was observed in the mean levels of lipids. Other laboratory parameters remained stable during the designated treatment period of 12 wk. Also, no side-effects were reported. Hence, it is concluded that Vijayasar is useful in the treatment of newly diagnosed or untreated mild NIDDM patients.
    Original languageEnglish
    Pages (from-to)24-9
    Number of pages6
    JournalThe Indian Journal of Medical Research
    Volume108
    Publication statusPublished - 1998

    Fingerprint

    Medical problems
    Type 2 Diabetes Mellitus
    Blood Glucose
    Biomedical Research
    Fasting
    Pterocarpus
    Lipids
    Therapeutics
    Pharmaceutical Preparations
    India

    Keywords

    • Adult
    • Blood Glucose
    • Diabetes Mellitus, Type 2
    • Hemoglobin A, Glycosylated
    • Humans
    • Medicine, Ayurvedic
    • Middle Aged

    Cite this

    @article{a59e7cba9b2f48c38266c72cdfef43e5,
    title = "Flexible dose open trial of Vijayasar in cases of newly-diagnosed non-insulin-dependent diabetes mellitus. Indian Council of Medical Research (ICMR), Collaborating Centres, New Delhi",
    abstract = "A flexible dose open trial was undertaken in four centres in India to evaluate the efficacy of an Ayurvedic drug Vijayasar (Pterocarpus marsupium) in the treatment of newly-diagnosed or untreated non-insulin dependent diabetes mellitus (NIDDM). By 12 wk, control of blood glucose (both fasting and postprandial levels) had been attained in 67 (69{\%}) of 97 patients studied, and the dose on which control was attained was 2 g of the extract in about 73 per cent of the patients, 3 g in about 16 per cent and 4 g in 10 per cent of the patients. Four patients had to be withdrawn from treatment due to excessively high postprandial blood glucose levels. Among the 93 patients who completed 12 wk of treatment, both the fasting and postprandial blood glucose levels fell significantly (P <0.001), by 32 and 45 mg/dl at 12 wk from the initial means of 151 and 216 mg/dl respectively. Mean HbA1c decreased significantly (P <0.001) to 9.4 per cent at 12 wk from the initial mean of 9.8 per cent. No significant change was observed in the mean levels of lipids. Other laboratory parameters remained stable during the designated treatment period of 12 wk. Also, no side-effects were reported. Hence, it is concluded that Vijayasar is useful in the treatment of newly diagnosed or untreated mild NIDDM patients.",
    keywords = "Adult, Blood Glucose, Diabetes Mellitus, Type 2, Hemoglobin A, Glycosylated, Humans, Medicine, Ayurvedic, Middle Aged",
    author = "Sam Philip",
    year = "1998",
    language = "English",
    volume = "108",
    pages = "24--9",
    journal = "The Indian Journal of Medical Research",
    issn = "0971-5916",
    publisher = "Indian Council of Medical Research",

    }

    TY - JOUR

    T1 - Flexible dose open trial of Vijayasar in cases of newly-diagnosed non-insulin-dependent diabetes mellitus. Indian Council of Medical Research (ICMR), Collaborating Centres, New Delhi

    AU - Philip, Sam

    PY - 1998

    Y1 - 1998

    N2 - A flexible dose open trial was undertaken in four centres in India to evaluate the efficacy of an Ayurvedic drug Vijayasar (Pterocarpus marsupium) in the treatment of newly-diagnosed or untreated non-insulin dependent diabetes mellitus (NIDDM). By 12 wk, control of blood glucose (both fasting and postprandial levels) had been attained in 67 (69%) of 97 patients studied, and the dose on which control was attained was 2 g of the extract in about 73 per cent of the patients, 3 g in about 16 per cent and 4 g in 10 per cent of the patients. Four patients had to be withdrawn from treatment due to excessively high postprandial blood glucose levels. Among the 93 patients who completed 12 wk of treatment, both the fasting and postprandial blood glucose levels fell significantly (P <0.001), by 32 and 45 mg/dl at 12 wk from the initial means of 151 and 216 mg/dl respectively. Mean HbA1c decreased significantly (P <0.001) to 9.4 per cent at 12 wk from the initial mean of 9.8 per cent. No significant change was observed in the mean levels of lipids. Other laboratory parameters remained stable during the designated treatment period of 12 wk. Also, no side-effects were reported. Hence, it is concluded that Vijayasar is useful in the treatment of newly diagnosed or untreated mild NIDDM patients.

    AB - A flexible dose open trial was undertaken in four centres in India to evaluate the efficacy of an Ayurvedic drug Vijayasar (Pterocarpus marsupium) in the treatment of newly-diagnosed or untreated non-insulin dependent diabetes mellitus (NIDDM). By 12 wk, control of blood glucose (both fasting and postprandial levels) had been attained in 67 (69%) of 97 patients studied, and the dose on which control was attained was 2 g of the extract in about 73 per cent of the patients, 3 g in about 16 per cent and 4 g in 10 per cent of the patients. Four patients had to be withdrawn from treatment due to excessively high postprandial blood glucose levels. Among the 93 patients who completed 12 wk of treatment, both the fasting and postprandial blood glucose levels fell significantly (P <0.001), by 32 and 45 mg/dl at 12 wk from the initial means of 151 and 216 mg/dl respectively. Mean HbA1c decreased significantly (P <0.001) to 9.4 per cent at 12 wk from the initial mean of 9.8 per cent. No significant change was observed in the mean levels of lipids. Other laboratory parameters remained stable during the designated treatment period of 12 wk. Also, no side-effects were reported. Hence, it is concluded that Vijayasar is useful in the treatment of newly diagnosed or untreated mild NIDDM patients.

    KW - Adult

    KW - Blood Glucose

    KW - Diabetes Mellitus, Type 2

    KW - Hemoglobin A, Glycosylated

    KW - Humans

    KW - Medicine, Ayurvedic

    KW - Middle Aged

    M3 - Article

    VL - 108

    SP - 24

    EP - 29

    JO - The Indian Journal of Medical Research

    JF - The Indian Journal of Medical Research

    SN - 0971-5916

    ER -